worldwid
cardiovascular
diseas
cvd
includ
coronari
heart
diseas
chd
stroke
lead
caus
mortal
increas
preval
nation
clinic
guidelin
atherosclerot
cardiovascular
diseas
account
million
deathsyear
million
europ
stone
et
al
death
unit
state
graham
et
al
lloydjon
et
al
project
increas
death
case
mendi
et
al
overal
risk
chd
determin
multipl
paramet
dyslipidemia
hypertens
smoke
diabet
mellitu
obes
coagulopathi
diet
sedentari
lifestyl
well
hereditari
genet
variat
roger
et
al
prospect
studi
collabor
risk
factor
account
populationattribut
risk
cvd
yusuf
et
al
cvd
could
prevent
prevent
treatment
risk
modal
mendi
et
al
dyslipidemia
mainli
hypercholesterolemia
play
causal
role
pathogenesi
atherosclerosi
respons
develop
progress
chd
stroke
peripher
vascular
diseas
roger
et
al
nine
independ
risk
factor
cvd
dyslipidemia
associ
highest
populationattribut
risk
cvd
case
directli
assign
lipid
yusuf
et
al
consequ
lower
modifi
plasma
lipid
level
becom
one
import
option
treatment
prevent
combat
lead
kill
diseas
world
expert
panel
detect
evalu
treatment
high
blood
cholesterol
adult
take
million
live
year
rozman
monostori
dyslipidemia
defin
spectrum
deviat
lipid
homeostasi
character
elev
plasma
concentr
lowdens
lipoprotein
ldl
lipoprotein
lp
apolipoprotein
b
triglycerid
tg
well
decreas
plasma
level
highdens
lipoprotein
hdl
apolipoprotein
apoai
primari
dyslipidemia
result
mutat
protein
involv
critic
pathway
involv
lipid
lipoprotein
metabol
ldl
receptor
famili
hypercholesterolemia
fh
apolipoprotein
b
famili
defect
variant
fh
case
dyslipidemia
secondari
caus
result
diseas
health
condit
diabet
hypothyroid
sedentari
lifestyl
overcalor
nutrit
decreas
physic
exercis
excess
alcohol
consumpt
age
gener
popul
also
contribut
grow
incid
hypercholesterolemia
plasma
level
ldlc
exert
natur
rise
increas
lifetim
schaefer
et
al
plasma
cholesterol
level
lowest
immedi
birth
mgdl
total
cholesterol
mgdl
ldlc
parker
et
al
dietschi
turley
onset
breast
feed
total
cholesterol
level
rapidli
increas
mgdl
due
high
cholesterol
content
breast
milk
epidemiolog
studi
nhane
iii
show
mean
total
cholesterol
level
adolesc
age
mgdl
lifetim
cholesterol
level
gradual
increas
healthi
subject
consum
typic
western
diet
mean
total
cholesterol
level
rise
around
mgdl
cohen
et
al
martin
et
al
compar
wildforg
nonprim
ldlc
level
mgdl
total
cholesterol
mgdl
human
much
higher
plasma
cholesterol
concentr
probabl
result
chang
eat
habit
lowcarbohydratehigh
protein
rich
diet
greater
consumpt
grain
anim
meat
rich
satur
fat
mann
patholog
examin
know
earliest
stage
atherogen
process
detect
coronari
arteri
alreadi
adolesc
earli
adulthood
strong
mcgill
newman
et
al
young
men
mean
age
year
kill
korean
vietnam
war
alreadi
detect
fibrou
plaqu
mcnamara
et
al
patholog
examin
individu
age
rang
year
die
noncardiovascular
reason
reveal
increas
fatti
streak
lesion
increas
age
posit
correl
lesion
plasma
cholesterol
level
mcgill
et
al
epidemiolog
studi
shown
continu
relationship
total
plasma
cholesterol
level
risk
coronari
heart
diseas
nation
heart
foundat
australia
new
zealand
reduct
plasma
ldlcnonhdlc
correl
reduct
cvd
event
wherea
increas
hdlc
decreas
cvd
event
keef
et
al
sack
expert
group
hdl
cholesterol
major
caus
role
elev
level
ldl
cholesterol
atherosclerot
vascular
diseas
unequivoc
proven
clinic
landmark
studi
reduct
plasma
ldl
cholesterol
level
statin
inhibitor
cholesterol
biosynthesi
scandinavian
simvastatin
surviv
studi
group
down
et
al
shepherd
et
al
surgic
interrupt
enterohepat
circul
bile
acid
buchwald
et
al
reduc
cardiovascular
morbid
death
metaanalysi
clinic
trial
particip
reveal
signific
risk
reduct
statin
therapi
cholesterol
treatment
trialist
ctt
collabor
et
al
cvd
coronari
event
ridker
stroke
ridker
coronari
revascular
ridker
reduct
plasma
ldlc
level
mmoll
mgdl
cochran
review
random
clinic
trial
particip
statin
therapi
result
reduct
total
mortal
combin
fatal
nonfat
cvd
event
taylor
et
al
ie
primari
prevent
dyslipidemia
work
year
fewer
death
case
coronari
heart
diseas
compar
regist
unit
state
introduct
statin
therapi
clinic
practic
wherebi
percentag
could
directli
align
decreas
total
plasma
cholesterol
level
ford
et
al
similarli
decreas
chd
mortal
report
canada
reduct
associ
improv
control
lipid
blood
pressur
wijeysundera
et
al
mean
age
particip
statin
trial
year
wijeysundera
et
al
rais
question
whether
efficaci
ldlc
lower
therapi
reduct
chd
event
would
higher
initi
earlier
life
base
observ
studi
correl
atherosclerot
lesion
plasma
cholesterol
level
increas
lifetim
strong
mcgill
newman
et
al
mcnamara
et
al
mcgill
et
al
find
elev
cholesterol
level
earli
adulthood
associ
cvd
later
life
pearson
et
al
observ
lower
ldlc
level
stop
progress
coronari
atherosclerot
lesion
obvious
linearli
correl
plasma
ldlc
level
achiev
indic
intens
lower
ldlc
lead
less
plaqu
progress
suggest
lower
elev
ldlc
level
earli
life
effect
preventionprogress
chdcvd
onset
therapi
later
life
ferenc
mahajan
despit
quantum
leap
treatment
dyslipidemia
introduct
statin
clinic
practic
major
gap
manag
lipid
disord
persist
statin
undoubtedli
therapi
prevent
cvd
almost
popul
group
except
sever
renal
cardiac
failur
saydah
et
al
address
entir
spectrum
cvd
risk
residu
risk
major
vascular
event
remain
high
year
despit
optim
manag
ldlc
level
statin
cholesterol
treatment
trialist
ctt
collabor
et
al
howev
highrisk
patient
attain
standard
ldlc
target
recommend
guidelin
exampl
patient
fh
mix
dyslipidemia
secondari
metabol
syndrom
increas
risk
due
risk
factor
low
hdl
high
tg
nonlipid
risk
factor
barnett
et
al
particularli
patient
complex
metabol
diseas
like
diabet
mellitu
signific
improv
control
risk
factor
necessari
adult
diabet
nhane
survey
attain
recommend
target
treatment
hyperglycemia
dyslipidemia
hypertens
saydah
et
al
relationship
total
plasma
cholesterol
chd
risk
continu
linear
risk
chd
rise
strongli
higher
ldlc
level
schaefer
et
al
indic
involv
risk
factor
howev
unequivoc
evid
random
clinic
trial
reduct
risk
factor
like
low
hdl
hdlc
elev
tg
nonlipid
influenc
like
hypertens
inflamm
diabet
reduc
risk
chd
therefor
number
patient
cvd
avail
hypertens
sever
et
al
recent
metaanalysi
lipid
gwasstudi
individu
european
descent
genet
loci
associ
serum
lipid
trait
identifi
mani
harbor
gene
involv
lipid
metabol
like
hmgcoa
reductas
hydroxylas
protein
target
avail
lipidlow
drug
mani
newli
identifi
gene
repres
possibl
new
risk
factor
pharmacolog
target
monitor
treat
cad
teslovich
et
al
hdl
mediat
cholesterol
transport
peripher
tissu
liver
consid
import
regul
chd
risk
parker
et
al
dietschi
turley
cohen
et
al
invers
relationship
hdl
level
chd
risk
martin
et
al
hdlc
independ
risk
factor
cvd
superior
ldlc
predictor
cv
event
sever
et
al
heart
protect
studi
collabor
group
colhoun
et
al
increas
hdlc
mgdl
mmoll
associ
reduct
cvd
risk
curb
et
al
paradox
despit
unequivoc
role
hdl
independ
risk
factor
cvd
event
failur
recent
clinic
trial
drug
aim
increas
hdlc
level
may
suggest
function
hdl
particl
rather
height
hdlc
level
relev
cardio
atheroprotect
efficaci
hdl
particl
due
complex
metabol
hdl
particl
involv
mani
differ
protein
interact
lipoprotein
particl
impact
mutat
key
protein
hdlparticl
pathway
cv
risk
fulli
understood
today
role
hdl
predictor
cv
diseas
still
valid
sens
hdlc
predictor
incid
cv
event
set
secondari
prevent
individu
alreadi
diagnos
cvd
rader
hovingh
conclus
low
hdlc
plasma
level
may
serv
strong
biomark
cvd
risk
predict
hdl
function
composit
consequ
measur
hdlc
metric
monitor
pharmacolog
efficaci
reduct
cvd
event
modul
hdl
particl
suffici
evalu
predict
efficaci
drug
approach
elev
hdl
level
kingwel
et
al
recent
result
popul
studi
involv
adult
free
cvd
mean
followup
year
investig
associ
hdl
level
function
paramet
primari
endpoint
cvd
nonfat
mi
nonfat
stroke
coronari
revascular
death
cvd
publish
rohatgi
et
al
wherea
baselin
level
hdl
found
associ
cv
event
cholesterol
efflux
capac
macrophag
key
compon
rct
process
identifi
reliabl
biomark
strongli
invers
associ
incid
cv
event
popul
cohort
littl
correl
found
cholesterol
efflux
capac
tradit
cv
risk
factor
coronari
arteri
calcium
marker
inflamm
cholesterol
efflux
macrophag
predominantli
catalyz
underlin
import
abc
transport
rct
find
conclud
measur
macrophagespecif
cholesterol
efflux
use
fluoresc
label
cholesterol
could
use
futur
reliabl
method
assess
sever
atherosclerosi
clinic
consequ
predict
efficaci
drug
approach
affect
hdl
metabol
reduct
cvd
risk
regard
caus
role
tg
cvd
event
pictur
well
realli
clear
observ
epidemiolog
studi
clinic
trial
use
drug
target
elev
tg
level
low
hdlc
level
indic
caus
predict
role
elev
tg
plasma
level
develop
primari
chd
recent
systemat
review
metaregress
analysi
random
control
trial
lipidmodifi
drug
chd
event
outcom
reveal
chang
plasma
tg
level
predict
cv
event
random
control
clinic
trial
significantli
primari
prevent
popul
secondari
prevent
popul
stauffer
et
al
plasma
tg
level
hdlc
metabol
mechanist
interconnect
via
lipid
metabol
exchang
protein
like
cetp
lpl
el
method
difficult
determin
rel
contribut
either
tg
hdlc
cvd
risk
lossoffunct
mutat
transport
decreas
plasma
hdlc
without
effect
tg
level
risk
chd
argu
direct
relationship
hdlc
chd
risk
potenti
explan
differ
predict
power
chang
tg
level
cv
event
primari
secondari
prevent
trial
elev
plasma
tg
level
could
still
risk
factor
secondari
popul
lower
import
total
risk
coronari
event
molecular
target
statin
enzym
reductas
ec
ratelimit
enzym
biosynthesi
pathway
mevalon
cholesterol
sterol
isoprenoid
lipid
like
dolichol
ubiquinon
detail
overview
statin
recent
review
articl
recommend
sirtori
shitara
sugiyama
statin
competit
enzym
inhibitor
compet
catalyt
bind
site
therebi
reduc
biosynthesi
rate
mevalon
downstream
product
like
cholesterol
decreas
intracellular
cholesterol
regulatori
pool
lead
upregul
ldl
receptor
hepatocyt
plasma
membran
lead
increas
clearanc
rate
ldl
particl
blood
therefor
fall
plasma
ldlc
level
overal
statin
reduc
ldlc
level
concomitantli
increas
hdlc
decreas
tg
vigna
fellin
toth
ewangemukowh
wierzbicki
tabl
base
dosag
atorvastatin
rosuvastatin
potent
statin
polar
compound
pravastatin
rosuvastatin
metabol
cytochrom
enzym
particularli
therefor
less
prone
interact
medic
due
cytochrom
metabol
highdos
therapi
statin
reduct
ldlc
achiev
find
howev
whenev
statin
dose
doubl
ldlc
level
reduc
addit
role
limit
clinic
efficaci
statin
use
steep
increas
incid
advers
side
effect
high
statin
dose
elev
plasma
transaminas
level
muscl
toxic
myalgia
sever
rhabdomyolysi
associ
high
statin
dose
therebi
limit
toler
dose
statin
achiev
reduct
plasma
ldlc
level
addit
benefici
effect
statin
plasma
lipid
profil
activ
statin
discuss
contribut
efficaci
reduct
cvd
event
final
proof
caus
role
pleiotrop
statin
effect
still
proven
statin
improv
endotheli
function
lead
vasodil
li
inhibit
inflammatori
process
reduct
circul
crp
level
pleng
et
al
well
stabil
plaqu
mayb
inhibit
myocyt
infiltr
inhibit
metalloproteinas
secret
massaro
et
al
sinc
inhibit
biosynthesi
cascad
cholesterol
statin
occur
earli
step
potenti
risk
seen
approach
due
decreas
lipid
like
ubiquinon
dolichol
manifest
decreas
nonsterol
lipid
advers
side
effect
differ
organ
includ
liver
muscl
eye
brain
today
year
broad
clinic
use
million
patient
treat
statin
consid
effect
safe
drug
current
million
american
peopl
dyslipidemia
take
statin
accord
recent
recommend
use
anoth
million
expect
benefit
statin
treatment
patient
known
cvd
new
guidelin
american
colleg
cardiolog
american
heart
associ
manag
cholesterol
recommend
statin
treatment
regardless
ldlc
level
pencina
et
al
public
health
guidelin
current
discuss
usa
uk
would
fulli
implement
one
third
middleag
adult
popul
countri
recommend
statin
therapi
pencina
et
al
safeti
toler
statin
treatment
good
except
myalgia
major
advers
side
effect
inde
statininduc
myalgia
frequent
phenomenon
clinic
practic
observ
patient
treat
statin
toth
et
al
wherea
fortun
frequenc
sever
lifethreaten
rhabdomyolysi
low
patient
treat
cholesterol
treatment
trialist
ctt
collabor
et
al
statin
taken
liver
hepatocyt
organ
anion
transport
polypeptid
found
genet
variant
gene
associ
risk
myopathi
upon
statin
treatment
carr
et
al
variant
exert
diminish
affin
transport
activ
statin
lead
reduc
hepat
uptak
result
higher
blood
level
increas
muscl
exposur
increas
offtarget
activ
neuromuscular
endplat
statin
power
inhibitor
chlorid
channel
muscl
cell
membran
pierno
et
al
potenti
lead
paralysi
addit
mechan
possibl
involv
statininduc
myopathi
diminish
ubiquinon
level
plasma
muscl
due
inhibit
synthesi
liver
induct
involv
skelet
muscl
atrophi
hanai
et
al
direct
antagonist
effect
statin
muscl
differenti
martini
et
al
mild
elev
serum
transaminas
occur
statintr
patient
doserel
indic
high
liver
safeti
statin
vigna
fellin
evid
slightli
increas
incid
type
diabet
acut
renal
failur
report
observ
data
addit
case
type
diabet
may
occur
everi
individu
treat
statin
year
indic
increas
risk
develop
diabet
sattar
et
al
acut
renal
failur
mayb
doserel
advers
side
effect
statin
low
incid
dormuth
et
al
develop
statin
cataract
issu
due
find
dog
studi
recent
retrospect
analysi
gave
evid
slightli
increas
incid
cataract
format
patient
treat
statin
leuschen
et
al
today
evid
regard
earli
concern
statin
use
may
impair
cognit
function
shepherd
et
al
contrast
patient
treat
statin
shown
reduc
risk
develop
alzheim
diseas
corrao
et
al
well
evid
increas
risk
cancer
cancer
mortal
found
treatment
statin
ridker
introduct
inhibitor
hmgcoa
reductas
statin
clinic
practic
dramat
chang
landscap
treatment
regimen
treatment
lipid
disord
coronari
event
stroke
reduc
respect
law
et
al
sever
metaanalys
statin
trial
reveal
reduct
cvd
risk
mmoll
ldllower
cholesterol
treatment
trialist
ctt
collabor
et
al
overal
mortal
respect
taylor
et
al
nevertheless
overal
mortal
chd
increas
futur
due
increas
incid
metabol
disord
like
obes
diabet
metabol
syndrom
despit
optim
drug
therapi
statin
signific
proport
patient
fail
achiev
recommend
level
ldl
cholesterol
schectman
hiatt
hsu
et
al
defin
european
us
guidelin
catapano
reason
treatment
failur
manifold
includ
follow
factor
poor
complianc
due
discomfort
side
effect
still
around
statintr
patient
discontinu
therapi
year
jackeviciu
et
al
recommend
target
ldlc
highrisk
patient
fh
patient
mmoll
achiev
toler
statin
dose
due
rule
phenomenon
lead
insuffici
dose
avoid
steep
increas
advers
side
effect
upon
dose
escalationineffici
drug
class
statin
intoler
hsu
et
al
larosa
et
al
bile
acid
sequestr
polymer
anionbind
resin
strongli
bind
neg
charg
bile
acid
lumen
small
intestin
therebi
interrupt
enterohepat
circul
bile
acid
et
al
block
intestin
bile
acid
reabsorpt
amount
andor
composit
bile
acid
recircul
liver
chang
lead
increas
hepat
bile
acid
synthesi
cholesterol
via
involv
nuclear
receptor
fxr
shp
deplet
regulatori
hepat
cholesterol
pool
induc
stimul
cholesterol
biosynthesi
via
upregul
hmgcoa
reductas
ldlreceptor
express
hepatocyt
surfac
latter
lead
increas
hepatocellular
uptak
ldl
particl
consequ
decreas
plasma
ldlcholesterol
level
current
three
bile
acid
sequestr
market
cholestyramin
colestipol
colesevelam
cholestyramin
colestipol
use
daili
dosag
g
wherea
recommend
daili
dose
colesevelam
g
high
necessari
dose
cholestyramin
colestipol
caus
occup
major
anionbind
site
chlorid
anion
competit
anion
bile
acid
wherea
cholestyramin
colestipol
show
prefer
dihydroxi
bile
acid
colesevelam
bind
bile
acid
ionic
hydrophob
interact
therebi
increas
bind
affin
specif
result
significantli
lower
necessari
dose
treatment
sequestr
safe
due
nonsystem
mode
action
within
lumen
intestin
sequestr
show
system
toxic
effect
nonabsorb
also
use
pregnanc
necessari
high
dose
sequestr
cholestyramin
colestipol
respons
major
advers
side
effect
gastrointestin
tract
constip
abdomin
pain
flatul
nausea
caus
complianc
issu
high
rate
treatment
discontinu
firstgener
sequestr
andrad
et
al
colesevelam
due
improv
bind
characterist
advers
side
effect
high
complianc
davidson
et
al
bind
characterist
anion
hydrophob
compound
chronic
use
sequestr
may
decreas
absorpt
fatsolubl
vitamin
nutrient
interfer
intestin
absorpt
drug
influenc
pharmacodynam
particularli
import
drug
narrow
therapeut
window
anticoagul
digitali
thiazid
thyroxin
case
time
lack
intak
respect
drug
sequestr
recommend
monotherapi
sequestr
decreas
ldlc
level
increas
hdlc
level
hou
goldberg
firstgener
sequestr
may
lead
undesir
increas
plasma
triglycerid
level
significantli
less
case
colesevelam
chang
composit
bile
acid
pool
enrich
trihydoxi
bile
acid
due
higher
bind
affin
dihydroxi
bile
acid
cholestyramin
colestipol
less
potent
trihydroxi
bile
acid
fxr
agonist
lead
decreas
fxr
activ
decreas
express
apocii
activ
lipoprotein
lipas
reduct
fxrmediat
inhibit
hepat
tg
synthesi
via
shp
kast
et
al
result
increas
tg
synthesi
decreas
tg
clearanc
vasculatur
induc
overal
increas
circul
tg
bile
acid
sequestr
proven
efficaci
reduc
chd
hou
goldberg
cvd
event
reduc
cholestyramin
addit
effect
upon
coadministr
statin
lipid
research
clinic
investig
addit
activ
bile
acid
sequestr
make
ideal
partner
comed
statin
patient
statin
therapi
suffici
enough
coadministr
colesevelam
statin
significantli
lower
ldlc
level
addit
patient
reach
therapeut
target
mgdl
ldlc
compar
treat
statin
alon
bay
et
al
colesevelam
abl
reduc
well
serum
level
crp
bay
et
al
increas
ldl
particl
size
indic
addit
inhibitori
effect
inflammatori
process
involv
atherogenesi
deveraj
et
al
recent
studi
strengthen
earli
observ
bile
acid
sequestr
addit
cholesterollow
activ
improv
glycem
control
patient
type
diabet
handelsman
et
al
colesevelam
approv
first
bile
acid
sequestr
treatment
type
diabet
clinic
trial
prediabet
individu
colesevelam
addit
improv
lipid
profil
reduc
fast
blood
glucos
level
valu
respect
fast
blood
glucos
level
valu
patient
treat
antidiabet
drug
could
reduc
upon
coadministr
colesevelam
goldberg
et
al
mechan
wherebi
bile
acid
sequestr
improv
glycem
control
yet
fulli
understood
may
involv
follow
contribut
increas
secret
incretin
like
due
spillov
bile
acid
colon
suzuki
et
al
chang
composit
bile
acid
pool
activ
fxr
downstream
activ
like
repress
hepat
gluconeogenesi
increas
insulin
sensit
zhang
et
al
activ
receptor
colon
bile
acid
spillov
stimul
energi
expenditur
thoma
et
al
proven
efficaci
bile
acid
sequestr
improv
atherogen
lipid
profil
reduct
chd
event
safeti
profil
nonsystem
mode
action
benefici
effect
glucos
homeostasi
strengthen
role
valu
bile
acid
sequestr
particularli
treatment
patient
statin
intoler
type
diabet
metabol
syndrom
ezetimib
exert
hypolipidem
action
inhibit
intestin
cholesterol
absorpt
ezetimib
target
pathway
key
regul
cholesterol
uptak
enterocyt
brush
border
membran
reuptak
cholesterol
bile
hepatocyt
cholesterol
solubil
mix
micel
transfer
enterocyt
brush
border
membran
via
proteinmedi
process
cai
et
al
kramer
et
al
move
detergentresist
microdomain
cholesterol
absorpt
occur
clathrindepend
receptormedi
endocytosi
involv
complex
clathrin
adaptor
protein
complex
wang
song
storag
socal
endocyt
recycl
compart
cholesterolsens
protein
cycl
compart
brush
border
membran
depend
cholesterol
level
sens
brush
border
membran
intracellular
cholesterol
level
low
aid
microfila
recycl
brush
border
membran
therebi
initi
stimul
microdomain
endocytot
process
ezetimib
specif
inhibit
pathway
controversi
regard
primari
molecular
target
ezetimib
postul
molecular
target
ezetimib
protein
better
yu
howev
direct
bind
ezetimib
label
techniqu
never
realli
demonstr
use
fluoresc
ezetimib
glucuronid
specif
bind
surfac
hek
cell
express
shown
garciacalvo
et
al
well
explain
role
form
protein
complex
necessari
clathrinmedi
endocytosi
wang
song
therebi
allow
access
ezetimib
primari
molecular
target
put
differ
contrast
direct
specif
bind
ezetimib
aminopeptidas
n
demonstr
extens
photoaffin
label
studi
variou
photoreact
ezetimib
analogu
well
isol
ezetimibebind
protein
affin
chromatographi
ezetimib
affin
matrix
sequenc
analysi
purifi
radiolabel
ezetimibebind
protein
affinitypurifi
ezetimibebind
protein
unequivoc
demonstr
ident
aminopeptidas
n
wherea
amino
acid
sequenc
found
isol
ezetimibebind
protein
kramer
et
al
frick
et
al
indic
aminopeptidas
n
primari
target
ezetimib
process
endocytosi
cholesterol
cholesterolrich
microdomain
enterocyt
brush
border
membran
skov
et
al
membran
imperm
ezetimib
analogu
abl
inhibit
cholesterol
uptak
cell
well
vivo
indic
bind
outsid
enterocyt
brush
border
membran
suffici
inhibit
cholesterol
intern
kramer
et
al
cellular
local
apn
brush
border
membran
intracellular
storag
compart
socal
deep
apic
tubul
cholesteroldepend
case
enzymat
activ
apn
act
receptor
involv
endocytot
process
hansen
et
al
involv
endocytosi
variou
viru
class
like
corona
sar
cytomegali
yeager
et
al
uptak
cholesterol
mix
micel
cell
specif
inhibit
mask
apn
apnspecif
antibodi
kramer
et
al
independ
whether
cell
cholesteroldeplet
cyclodextrin
wherebi
concentr
brush
border
membran
larg
chang
cyclodextrin
treatment
find
indic
specif
bind
ezetimib
apn
block
intern
cholesterolrich
microdomain
therebi
prevent
cholesterol
absorpt
interrupt
sens
pathway
skov
et
al
ezetimib
drug
avail
inhibit
intestin
cholesterol
absorpt
monotherapi
ezetimib
decreas
serum
ldlc
decreas
tg
small
increas
effect
hdlc
bruckert
et
al
ezetimib
influenc
intestin
absorpt
bile
acid
fatsolubl
vitamin
caroten
ezetimib
show
signific
advers
side
effect
influenc
activ
cytochrom
enzym
therefor
devoid
signific
pharmacokinet
interact
drug
effect
ezetimib
ldlc
addit
statin
therefor
combin
ezetimib
statin
overcom
rule
doubl
statin
dose
ezetimibesimvastatin
combin
mg
ezetimib
mg
simvastatin
reduc
ldlc
respect
ballantyn
et
al
addit
effect
statin
lack
necessari
titrat
statin
dose
make
combin
ezetimib
statin
import
option
patient
resist
intoler
statin
larg
clinic
trial
howev
like
enhanc
patient
heterozyg
fh
reveal
statist
signific
effect
carotid
intima
media
thick
compar
simvastatin
alon
despit
higher
ldlc
lower
efficaci
combin
kastelein
et
al
two
trial
sea
simvastatin
ezetimib
aortic
stenosi
sharp
studi
heart
renal
protect
howev
signific
risk
reduct
cvd
event
observ
proport
reduct
ldlc
rossebo
et
al
baigent
et
al
conclus
answer
regard
clinic
relev
benefici
effect
ezetimib
cardiovascular
morbid
mortal
await
ongo
improveit
studi
cover
patient
acut
coronari
syndrom
compar
treatment
regimen
simvastatin
vs
combin
ezetimib
peroxisom
prolifer
activ
receptor
nuclear
receptor
subfamili
group
c
nuclear
transcript
factor
major
regul
lipid
metabol
liver
exert
activ
modifi
express
larg
number
target
gene
predominantli
involv
fatti
acid
transport
metabol
gluconeogenesi
endogen
ligand
compris
fatti
acid
eicosanoid
includ
leukotrien
bind
agonist
ligandbind
domain
induc
conform
chang
lead
sequestr
number
coactiv
corepressor
protein
activ
receptor
heterodimer
retinoid
x
receptor
rxr
follow
bind
ppar
respons
element
ppre
promot
target
gene
initi
modif
express
fibrat
synthet
ligand
select
mimick
natur
fatti
acid
ligand
activ
therebi
orchestr
via
target
gene
adapt
bodi
energi
depriv
stimul
mitochondri
peroxisom
inhibit
hepat
vldl
product
inhibit
activ
activ
lpl
deliv
free
fatti
acid
metabol
energi
gener
latter
mediat
reduct
express
lpl
inhibitor
apociii
induct
lplactiv
apocii
result
tg
hydrolysi
vldl
chylomicron
particl
stimul
lead
strong
decreas
circul
tg
level
result
tgpoor
ldl
particl
remnant
show
higher
affin
ldl
receptor
result
increas
clearanc
accompani
decreas
ldlc
level
fibrat
modifi
ldlparticl
size
small
dens
ldlparticl
characterist
diabet
dyslipidemia
larg
less
atherogen
one
gazi
et
al
addit
hdlc
level
increas
fibrat
due
stimul
hepat
express
product
apolipoprotein
apoai
apoaii
well
diminish
load
hdl
particl
tg
wherebi
result
hdl
particl
becom
less
sensit
catabol
hepat
lipas
overal
revers
cholesterol
transport
stimul
process
current
three
fibrat
clinic
use
fenofibr
gemfibrozil
bezafibr
fenofibr
prefer
drug
owe
lack
pk
interact
statin
clinic
use
fibrat
effici
reduc
serum
tg
concentr
increas
hdlc
level
modest
ldlc
lower
effect
due
lipidmodifi
profil
fibrat
particularli
use
monotherapi
combin
statin
treatment
patient
diabet
dyslipidemia
metabol
syndrom
fievet
stael
larg
outcom
studi
diabet
patient
field
fenofibr
intervent
event
lower
diabet
involv
type
diabet
patient
field
studi
investig
accord
action
control
cardiovascular
risk
diabet
diabet
patient
receiv
either
simvastatin
mgday
combin
mgday
simvastatin
mgday
fenofibr
accord
studi
group
reduct
macrovascular
event
like
chd
coronari
death
nonfat
mi
could
demonstr
howev
microvascular
event
includ
retinopathi
nephropathi
neuropathi
significantli
reduc
metaanalysi
reveal
patient
low
hdlc
mmoll
high
tg
plasma
level
mmoll
benefit
treatment
fenofibr
sack
et
al
toler
safeti
fibrat
accept
advers
side
effect
includ
myopathi
upper
gisymptom
mild
elev
serum
transaminas
homocystein
level
increas
incid
cholesterol
gallston
prueksaritanont
et
al
sever
advers
side
effect
muscl
toxic
rhabdomyolysi
davidson
et
al
particularli
gemfibrozil
treatment
combin
statin
associ
increas
risk
myopathi
hepatotox
caus
competit
statin
glucuronid
elimin
pathway
therebi
decreas
elimin
statin
prueksaritanont
et
al
lipid
profilemodifi
effect
vitamin
nicotin
acid
niacin
sinc
nearli
year
introduc
clinic
practic
carlson
pharmacolog
dose
gday
niacin
exert
signific
chang
differ
lipoprotein
increas
hdlc
apoai
product
lamonfava
et
al
combin
decreas
ldlc
tg
lp
well
reduct
fibrinogen
plasminogen
activ
inhibitor
pai
niacin
current
potent
drug
market
increas
hdlc
approv
drug
signific
reduct
independ
cv
risk
factor
lp
perspect
profil
niacin
reduct
atherogen
lipoprotein
increas
antiatherogen
lipoprotein
reduct
prothrombot
factor
princip
close
ideal
drug
target
profil
treat
dyslipidemia
particularli
patient
diabet
dyslipidemia
howev
clinic
benefit
lipid
profil
niacin
overshadow
number
shortcom
hamper
therapeut
valu
clinic
practic
includ
poor
complianc
due
unpleas
side
effect
flush
mediat
activ
prostaglandin
receptor
control
neg
affect
increas
fast
blood
glucos
level
insulin
level
decreas
insulin
sensit
sever
week
high
niacin
dose
necessari
achiev
benefici
effect
lipid
pattern
normal
glucos
control
observ
week
goyal
et
al
indic
short
longterm
treatment
niacin
worsen
glycem
control
limit
use
particularli
patient
diabet
dyslipidemia
low
dose
nicotin
acid
minim
effect
glucos
toler
well
moder
effect
lipid
profilesincreas
plasma
level
uric
acid
promot
risk
gout
attacksliv
toxic
gastrointestin
side
effect
overcom
clinic
promin
uncomfort
side
effect
flush
slow
releas
form
niacin
niaspan
develop
improv
handl
nicotin
acid
benefitadvers
side
effect
ratio
anoth
approach
increas
complianc
niacin
use
inhibit
flush
comed
inhibitor
laropipr
incid
flush
significantli
reduc
disappear
complet
due
fact
flush
also
induc
prostaglandin
vosper
despit
clinic
use
sinc
decad
molecular
mechan
niacin
mediat
pleiotrop
effect
lipid
mechan
fulli
understood
whole
plethora
molecular
target
mechan
report
niacin
wherea
effect
tg
metabol
quit
well
explain
molecular
term
mechan
wherebi
niacin
increas
hdlc
specul
scientif
argument
follow
mechan
niacin
report
ainhibit
tg
levelsniacin
potent
inhibit
lipolysi
adipos
tissu
activ
nicotin
acid
receptor
trigger
inhibit
adenyl
cyclas
consequ
decreas
camp
level
prevent
activ
pka
inhibit
hormonesensit
lipas
result
decreas
lipolysi
juliu
fischer
plasma
free
fatti
acid
liver
diminish
flux
free
fatti
acid
adipos
tissu
lead
suppress
express
well
apolipoprotein
result
decreas
secret
vldl
particl
direct
inhibit
enzym
nicotin
acid
limit
deliveri
tg
secret
vldl
particl
propos
relev
molecular
target
niacin
action
tg
synthesi
kamanna
et
al
decreas
content
tg
vldl
particl
increas
result
ldl
particl
size
addit
stimul
apob
catabol
plasma
ldl
vldl
level
decreas
furtherbincreas
hdlc
levelsth
hdl
effect
niacin
probabl
relat
activ
nicotin
acid
receptor
investig
ko
mice
specif
highaffin
ligand
demonstr
receptor
clearli
involv
niacin
pharmacolog
activ
tg
metabol
play
signific
role
hdl
effect
niacin
laur
et
al
explain
clinic
failur
highli
specif
agonist
strongli
inhibit
lipolysi
decreas
plasma
ffa
level
signific
effect
serum
lipid
profil
particularli
hdl
level
laur
et
al
recent
studi
explain
niacin
effect
hdl
inhibit
cetpmedi
lipid
exchang
result
cholesterolenrich
hdl
particl
reduct
hepat
clearanc
hdl
particl
well
stimul
revers
cholesterol
transport
increas
flux
cholesterol
hdl
mechan
suggest
involv
increas
express
product
nascent
hdl
particl
reduct
express
put
hepat
hdlreceptor
atp
synthas
result
inhibit
hdlparticl
clearanc
kamanna
et
al
ceffect
flushth
discoveri
specif
nicotin
acid
receptor
strongli
trigger
search
nonniacinrel
highaffin
ligand
receptor
led
assumpt
pleiotrop
benefici
effect
niacin
mediat
via
receptor
unfortun
new
drug
fail
increas
hdl
level
express
adipocyt
well
immun
cell
spleen
langerhan
cell
epidermi
kamanna
et
al
activ
latter
nicotin
acid
increas
product
caus
agent
undesir
side
effect
flush
therefor
flush
nondissoci
advers
side
effect
inhibit
lipolysi
agonist
like
niacin
make
search
better
niacin
less
side
effect
unlik
larg
clinic
trial
howev
niacin
fail
exert
signific
benefici
effect
cvd
event
aim
high
studi
perform
highrisk
patient
cvd
low
hdlc
ldlc
optim
treat
statin
reveal
signific
reduct
cvd
event
despit
strong
increas
hdlc
reduct
tg
investig
aimhigh
et
al
hand
combin
niacin
bile
acid
sequestr
lovastatin
result
regress
cad
kane
et
al
largest
hitherto
perform
drug
trial
niacin
trial
adult
vascular
diseas
ldlc
level
adjust
mg
simvastatin
mg
simvastatin
plu
mg
ezetimib
afterward
patient
randomli
assign
either
treatment
group
receiv
g
niacin
mg
laropipr
placebo
arm
observ
period
year
averag
ldlc
lower
addit
mmoll
hdlc
increas
mmoll
howev
signific
effect
incid
major
cvd
event
could
observ
vs
contrast
discontinu
rate
significantli
higher
niacinlaropipr
group
vs
advers
side
effect
reaction
well
increas
treatment
group
vs
patient
diabet
proport
increas
disturb
glucocontrol
higher
incid
newli
diagnos
diabet
found
niacinlaropipr
group
collabor
group
conclus
addit
slowreleas
niacinlaropipr
combin
patient
treat
statin
addit
benefici
effect
vascular
event
unfavor
outcom
final
led
withdraw
niacinstatinlaropipr
combin
market
leav
behind
signific
doubt
regard
benefit
niacin
treatment
dyslipidem
patient
rapidli
grow
field
drug
discoveri
treatment
dyslipidemia
obes
diabet
metabol
syndrom
search
dgat
inhibitor
dgat
catalyz
final
step
biosynthesi
tg
mammal
two
nonhomolog
enzym
encod
differ
gene
involv
tg
synthesi
local
predominantli
endoplasm
reticulum
wherea
also
associ
lipid
droplet
liu
et
al
interest
dgat
inhibitor
stimul
phenotyp
observ
dgat
ko
mice
ko
mice
reduc
tg
level
resist
dietinduc
obes
show
increas
insulin
sensit
smith
et
al
chen
fares
chen
et
al
ko
mice
show
similar
phenotyp
exert
sever
skin
abnorm
question
use
potenti
therapeut
target
howev
antisens
approach
demonstr
decreas
bodi
weight
adipos
tissu
hepat
tg
insulin
resist
without
skin
abnorm
may
indic
inhibitor
may
benefici
treatment
metabol
diseas
particularli
hepat
steatosi
nonalcohol
steatohepat
nash
current
least
four
small
molecul
inhibitor
clinic
preclin
develop
phase
iii
mostli
advanc
treatment
rare
famili
chylomicronemia
syndrom
hyperlipoproteinemia
type
random
placebo
control
clinic
studi
pradigastat
given
healthi
human
volunt
day
suppress
postprandi
tg
dosedepend
maxim
suppress
concomitantli
number
postprandi
chylomicron
particl
measur
level
also
reduc
associ
modest
reduct
fast
tg
cholesterol
level
myer
et
al
small
clinic
studi
six
patient
suffer
famili
chylomicronemia
syndrom
fc
treatment
mg
pradigastat
abl
reduc
plasma
tg
level
mgdl
nearli
exclus
reduct
chylomicron
tg
compound
well
toler
dose
test
mg
mild
transient
gastrointestin
side
effect
patient
seriou
advers
side
effect
discontinu
studi
occur
myer
et
al
dose
day
caus
weight
loss
improv
insulin
sensit
decreas
lipid
dispos
meal
reduc
hepat
steatosi
aicher
et
al
inhibit
antisens
drug
preclin
develop
attempt
treatment
nash
await
file
ind
applic
earli
wwwisispharmcompipelineindexhtm
drug
develop
acid
novel
regul
lipid
carbohydr
metabol
exert
uniqu
dual
mode
action
name
activ
ampk
inhibit
atpcitr
lyas
latter
mechan
exert
format
coenzym
thioester
within
liver
direct
inhibitor
atpcitr
lyas
pinkovski
et
al
investig
variou
clinic
trial
includ
four
phase
iia
doubleblind
placebocontrol
studi
cohort
hypercholesterolem
patient
differ
characterist
newton
et
al
one
hundr
seventyseven
hypercholesterolem
patient
normal
elev
tg
level
receiv
mg
week
show
reduct
ldlc
hscrp
vs
baselinein
type
diabet
patient
receiv
mg
week
ldlc
hscrp
level
reduc
respectivelyfiftysix
patient
statin
intoler
receiv
mg
week
show
reduct
ldlc
hscrp
vs
baselinein
hypercholesterolem
patient
treat
mgday
atorvastatin
addit
treatment
mgday
could
reduc
plasma
level
ldldc
hscrp
vs
baselin
drug
well
toler
hypercholesterolem
patient
histori
statin
intoler
treat
compar
placebo
lower
rate
musclerel
advers
event
vs
fewer
number
discontinu
musclerel
advers
effect
vs
show
sign
liver
toxic
increas
transaminas
uln
cpk
uln
newton
et
al
phase
studi
includ
hypercholesterolem
patient
week
efficaci
investig
monotherapi
vs
ezetimib
combin
ezetimib
monotherapi
mgday
lower
ldlc
hdcrp
vs
baselin
compar
mg
ezetimib
patient
treat
mg
ezetimib
receiv
addit
mgday
show
reduct
ldlc
hscrp
respect
press
releas
esperion
clinic
relev
chang
hdlc
tg
level
observ
compound
well
toler
associ
doselimit
side
effect
data
indic
potenti
safe
altern
treatment
hypercholesterolem
patient
assembl
vldl
particl
apolipoprotein
b
lipid
endoplasm
reticulum
hepatocyt
enterocyt
catalyz
mtp
consequ
inhibit
protein
would
reduc
secret
vldl
particl
liver
chylomicron
small
intestin
due
catabol
lipoprotein
ldl
inhibit
mtp
result
strong
decreas
plasma
ldl
particl
mtp
inhibitor
efficaci
lower
atherogen
apobcontain
lipoprotein
plasma
triglycerid
develop
hamper
limit
mechanismbas
advers
side
effect
lipid
accumul
liver
intestin
drawback
liver
toxic
hepat
steatosi
sequela
howev
patient
homozyg
fh
unrespons
current
lipid
therapi
reli
ldl
apheresi
patient
reduct
synthesi
rate
ldl
particl
inhibit
vldlchylomicron
assembl
would
new
therapeut
option
decemb
fda
approv
lomitapid
treatment
patient
homozyg
fh
adjunct
diet
lipidlow
therapi
includ
ldl
apheresi
phase
iii
clinic
trial
averag
reduct
ldlc
achiev
week
ldl
reduct
patient
receiv
mg
lomitapid
daili
addit
triglycerid
reduc
compar
placebo
patient
studi
show
mild
moder
gastrointestin
advers
effect
abdomin
discomfort
diarrhea
nausea
cuchel
et
al
order
limit
mechanismbas
appear
hepat
steatosi
inhibit
mtp
enterocyt
compound
inactiv
upon
entri
system
circul
metabol
inact
metabolit
result
phase
ii
clinic
trial
combin
metformin
week
type
diabet
patient
indic
signific
reduct
plasma
triglycerid
reduct
postprandi
free
fatti
acid
weight
loss
tong
et
al
phospholipas
involv
reshap
lipoprotein
pathogenesi
atherosclerosi
phospholipas
occur
two
form
secretori
associ
lipoprotein
overal
occur
isoform
found
associ
atherosclerot
lesion
rosenson
hurtcamejo
elev
level
link
increas
cvd
risk
packard
hydrolyz
glycophospholipid
surfac
vldl
ldl
particl
yield
lysophosphatid
oxid
unesterifi
free
fatti
acid
eicosanoid
latter
process
proinflammatori
mediat
like
prostanoid
leukotrien
lipoxin
addit
result
vldl
ldl
particl
less
effici
clear
apob
apo
receptor
liver
lead
increas
ldlc
level
ldl
particl
avidli
bound
macrophag
subsequ
receptormedi
intern
cholesterol
foster
foam
cell
format
due
function
atherogenesi
inhibitor
form
clinic
develop
long
time
darapladib
test
overal
patient
whether
could
significantli
reduc
rate
stroke
heart
attack
studi
effect
inflammatori
marker
arteri
stiff
atheroma
volum
could
discov
serruy
et
al
patient
chd
darapladib
show
dosedepend
inhibit
activ
accompani
mean
decreas
inflammatori
marker
crp
respect
month
treatment
mgday
darapladib
howev
differ
treatment
placebo
group
found
regard
plaqu
stabil
plasma
highsensit
crp
wherea
necrot
core
volum
plaqu
increas
placebo
group
darapladib
produc
decreas
core
volum
without
signific
differ
total
atheroma
volum
serruy
et
al
recent
publish
data
clinic
trial
inhibitor
disappoint
neither
varespladib
darapladib
solidtimi
trial
patient
acut
coronari
syndrom
stabil
trial
patient
chronic
chd
signific
reduct
major
coronari
event
could
found
stabil
investig
metaanalysi
studi
inhibitor
involv
overal
patient
show
correl
mass
activ
cvd
event
howev
adjust
apob
level
longer
correl
sinc
statin
reduc
number
apobcontain
lipoprotein
potenti
addit
effect
inhibit
probabl
margin
furthermor
inflammatori
pathway
highli
redund
pro
antiinflammatori
effect
may
overlap
impos
signific
doubt
rational
probabl
success
approach
thyroid
hormon
particularli
triiodothyronin
profound
effect
lipid
metabol
via
variou
mechan
increas
hepat
ldlreceptor
express
stimul
cholesterol
convers
bile
acid
activ
alpha
hydroxylas
pathway
increas
hepat
cholesterol
secret
upregul
abc
transport
stimul
rct
consequ
liverselect
thyromimet
compound
show
princip
desir
action
treatment
dyslipidemia
decreas
ldlc
tg
stimul
rct
thyroid
hormon
exert
pleiotrop
activ
mean
thyroid
receptor
cholesterollow
activ
mainli
mediat
receptor
isoform
predominantli
express
hepatocyt
wherea
receptor
respons
heart
rate
increas
effect
therefor
high
select
receptor
mandatori
avoid
cv
advers
side
effect
gullberg
et
al
initi
trial
natur
occur
thyroid
hormon
observ
spectrum
benefici
effect
dyslipidemia
stimul
search
safe
liverselect
thyromimet
eprotirom
investig
phase
iii
trial
treatment
hypercholesterolemia
dyslipidemia
studi
patient
statin
therapi
eprotiromeday
show
promis
result
reduct
ldlc
tg
lp
respect
small
decreas
hdlc
signific
advers
side
effect
heart
cardiovascular
function
observ
ladenson
et
al
develop
compound
termin
due
safeti
concern
reason
cartilag
damag
toxicolog
studi
dog
press
releas
karo
anoth
thyroid
hormon
receptor
agonist
soberitom
investig
phase
clinic
trial
show
ldlc
reduct
healthi
volunt
scanlan
compound
also
longer
develop
continu
interest
thyroid
hormon
analogu
overcom
mechanismbas
issu
document
recent
entri
two
new
thyromimet
compound
phase
clinic
trial
liverdirect
tr
agonist
lack
activ
receptor
without
observ
cardiovascular
activ
phase
clinic
trial
healthi
volunt
receiv
daili
dose
mg
week
compound
found
safe
without
signific
advers
side
effect
plasma
lipid
profil
benefici
influenc
decreas
ldlc
nonhdlc
apob
tg
indic
promis
profil
treatment
mix
dyslipidemia
taub
et
al
major
challeng
thyromimet
treatment
dyslipidemia
remain
unequivoc
demonstr
longterm
safeti
advanc
approach
aim
inhibit
interact
secret
ldl
receptor
either
neutral
antibodi
peptidomimet
mimick
contact
point
ldl
receptor
current
least
differ
monoclon
antibodi
clinic
develop
three
advanc
antibodi
evolocumab
alirocumab
aococizumab
rin
extens
data
clinic
studi
phase
ii
well
iii
evolocumab
alirocumab
publish
excel
overview
perform
run
clinic
data
found
paper
dadu
et
al
phase
clinic
trial
monotherapi
antibodi
reduc
ldlc
concomitantli
reduct
apob
cardiovascular
risk
factor
lp
reduc
three
drug
alirocumab
addit
decreas
tg
level
increas
hdlc
wherea
effect
paramet
found
evolocumab
signific
differ
regard
advers
side
effect
found
three
antibodi
common
advers
side
effect
inject
site
reaction
pain
local
rash
upper
respiratori
tract
infect
nasopharyng
gastrointestin
disturb
like
diarrhea
nausea
use
combin
lipidlow
drug
like
statin
ezetimib
antibodi
could
decreas
ldlc
phase
ii
clinic
trial
combin
statin
ezetimib
outstand
efficaci
block
antibodi
could
underpin
addit
statin
alirocumab
reduc
ldlc
lp
compar
evolocumab
respect
effect
drug
hdlc
increas
alirocumab
evolocumab
reduct
tg
level
well
compar
placebocontrol
trial
statintr
patient
week
bococizumab
dose
mg
twice
monthli
produc
mean
chang
ldlc
baselin
respect
ballantyn
et
al
wherea
phase
ii
trial
primarili
patient
primari
hypercholesterolemia
stabl
statin
dose
includ
ongo
plan
phase
iii
trial
includ
much
wider
spectrum
patient
dyslipidemia
statinintoler
naiv
lipid
therapi
without
combin
statin
ezetimib
fibrat
recent
publish
data
first
two
phase
iii
clinic
trial
allow
first
anticip
regard
potenti
impact
quantum
leap
treatment
lipid
disord
potenti
prevent
atherosclerosi
odyssey
longterm
trial
patient
high
cv
risk
heterogen
fh
treat
statin
anoth
lipidmodifi
therapi
treat
week
placebocontrol
studi
mg
alirocumab
sc
everi
fortnight
week
mean
reduct
ldlc
vs
increas
placebo
group
seventynin
percent
treat
patient
achiev
target
least
reduct
ldlc
baselin
discontinu
rate
similar
verum
placebo
arm
vs
respect
alirocumab
group
show
risk
reduct
absolut
rate
cv
event
vs
robinson
et
al
treatment
hypercholesterolem
patient
mg
alirocumab
everi
week
result
similar
reduct
ldlc
fortnightli
inject
press
releas
sanofi
within
descart
studi
hypercholesterolem
patient
stratifi
four
group
treat
diet
alon
mg
atorvastatin
mg
atorvastatin
mg
atorvastatin
plu
mg
ezetimib
receiv
addit
mg
evolocumab
sc
everi
week
mean
addon
reduct
could
achiev
supplement
evolocumab
addit
reduct
apob
nonhdlc
lp
tg
plasma
level
blom
et
al
patient
hofh
antibodi
also
efficaci
shown
recent
tesla
studi
patient
mean
ldlc
mgdl
week
treatment
mg
evolocumab
ldlc
reduc
compar
increas
nontreat
group
patient
mutat
ldl
receptor
reduct
could
demonstr
wherea
drug
effect
patient
devoid
ldl
receptor
raal
et
al
huge
phase
iii
clinic
outcom
trial
run
alirocumab
evolocumab
involv
odyssey
fourier
patient
respect
bococizumab
well
phase
iii
trial
involv
patient
plan
detail
overview
regard
clinic
trial
antibodi
see
excel
articl
dadu
et
al
conclus
result
trial
expect
allow
definit
judgment
regard
clinic
benefit
inhibit
cardiovascular
diseas
primari
outcom
paramet
megatri
time
occurr
one
follow
clinic
event
death
chd
nonfat
myocardi
infarct
stroke
hospit
due
unstabl
angina
summari
clinic
find
obtain
far
neutral
antibodi
encourag
demonstr
impress
reduct
ldlc
lp
level
translat
measur
clinic
benefit
patient
term
reduct
mortal
prevent
chd
antibodi
therapi
possess
high
longterm
safeti
altern
approach
monoclon
antibodi
block
interact
ldl
receptor
design
peptid
peptidomimet
interf
differ
contact
surfac
two
protein
drug
candid
mimick
cterminu
egfa
domain
ldl
receptor
adnectin
base
scaffold
human
fibronectin
engin
domain
prevent
interact
ldl
receptor
evalu
earli
preclin
clinic
trial
respect
mullard
monoclon
antibodi
mimet
tackl
function
secret
protein
sinc
also
intracellularli
involv
regul
ldlreceptor
surfac
express
approach
silenc
gene
theoret
even
effect
antisens
genesilenc
approach
evalu
advanc
regard
investig
drug
phase
clinic
trial
oral
activ
small
molecul
coval
conjug
niacin
eicosapentaeno
acid
molecul
system
inert
uptak
cell
prodrug
intracellularli
hydrolyz
pharmacolog
activ
drug
molecular
mechan
wherebi
inhibit
inhibit
process
srebp
kda
precursor
protein
activ
srebp
therebi
inhibit
activ
srebpregul
target
gene
zimmer
et
al
cell
express
reduc
well
due
pleiotrop
action
srebp
action
gene
like
hmgcoareductas
well
inhibit
leiden
mice
treat
week
compound
plasma
level
total
cholesterol
tg
reduc
respect
histolog
evalu
liver
show
increas
express
ldl
receptor
phase
clinic
trial
pathway
normal
healthi
volunt
n
receiv
mg
day
show
decreas
tg
level
dose
test
concomit
reduct
thr
plasma
level
nonhdlc
ldlc
donovan
et
al
plasma
level
nefa
increas
indic
compound
activ
nicotin
acid
receptor
furthermor
flush
observ
demonstr
system
activ
niacin
via
receptor
clinic
trial
ongo
among
studi
patient
chylomicronemia
hyperlipoproteinemia
type
ass
efficaci
safeti
small
molecul
origin
design
cetp
inhibitor
current
phase
clinic
trial
found
suppress
also
product
hepatocyt
cell
line
decreas
mrna
inhibit
srebp
bind
sterol
respons
element
sre
promot
region
gene
suppress
srebp
express
potenti
mechan
suggest
interfer
bind
transcript
factor
srebp
hinfp
close
neighbor
bind
site
promot
region
shibata
et
al
miyosawa
et
al
synthet
peptid
comb
amphipath
lipidbind
domain
apo
bind
domain
human
apo
receptor
abil
insert
phospholipid
surfac
apob
contain
lipoprotein
target
liver
dock
via
heparansulf
proteoglycan
receptor
syndecan
normocholesterolem
hypercholesterolem
cynomolgu
monkey
abl
reduc
total
cholesterol
level
infus
goldberg
et
al
firstinman
studi
compound
show
accept
safeti
profil
reduct
vldl
tg
vs
baselin
within
first
h
infus
press
releas
capston
treatment
mayb
effect
treatment
option
patient
lack
function
dysfunct
ldlreceptor
pathway
homozyg
heterozyg
fh
sever
refractori
hypercholesterolemia
epidemiolog
genet
studi
well
metaanalys
manifest
causal
independ
role
apolipoprotein
lp
cvd
particularli
myocardi
infarct
stroke
kolski
tsimika
lp
level
linearli
link
risk
cvd
lp
level
show
strong
heterogen
primarili
due
genet
variat
individu
modul
diet
lifestyl
chang
lp
mediat
atherogen
ldl
apolipoprotein
moieti
latter
atherogen
proinflammatori
properti
kringl
domain
effect
therapi
reduc
elev
lp
level
plasma
apheresi
result
lp
reduct
current
drug
approv
specif
lower
lp
drug
like
nicotin
acid
show
certain
efficaci
lower
lp
level
sever
lipidmodifi
drug
clinic
develop
well
investig
effect
lp
mipomersen
recent
approv
treatment
fh
show
lp
reduct
patient
heterozyg
homozyg
famili
fh
respect
visser
et
al
specif
design
antisens
nucleotid
apolipoprotein
abl
reduc
express
anim
merki
et
al
mtp
inhibitor
lomitapid
decreas
lp
modestli
samaha
et
al
antibodi
like
reduc
lp
level
hypercholesterolem
patient
dia
et
al
stein
et
al
cetp
inhibitor
anacetrapib
thyromimet
eprotirom
also
reduc
lp
level
novel
efficaci
approach
reduc
lp
seem
possibl
agonist
farnesoid
x
receptor
fxr
chennamseti
et
al
obetichol
acid
neuschwandertetri
et
al
press
releas
phenex
fxr
agonist
current
clinic
develop
treatment
nash
patient
statin
intoler
heterozyg
fh
reach
atp
iii
goal
ldlc
rana
boeckholdt
indic
signific
medic
need
efficaci
lipid
manag
patient
princip
antisens
oligonucleotid
aso
rna
silenc
technolog
ideal
suit
achiev
high
specif
inhibit
specif
function
particular
protein
downregul
synthesi
translat
level
therebi
minim
risk
interact
due
lack
involv
cytochrom
enzym
drug
metabol
particular
import
multimorbid
patient
often
receiv
multidrug
therapi
major
disadvantag
antisensedirect
therapi
limit
stabil
serum
cellular
nucleas
limit
permeabl
across
biolog
membran
well
offtarget
effect
interact
tolllik
receptor
jone
therefor
rnabas
antisens
drug
appli
parenter
thu
deliveri
target
tissu
cell
still
major
challeng
obstacl
rna
aso
drug
iv
inject
major
aso
accumul
liver
kidney
thu
make
therapeut
interest
drug
target
local
organ
prioriti
aso
therapi
hand
organotrop
remain
major
challeng
rna
dnabas
drug
act
tissu
liver
kidney
fortun
liver
major
organ
regul
lipid
homeostasi
metabol
therefor
aso
therapi
reliabl
approach
treat
dyslipidemia
block
express
target
gene
local
hepatocyt
apolipoprotein
apolipoprotein
mtp
particular
lock
nucleic
acidderiv
aso
promis
candid
wider
scope
applic
due
improv
compound
characterist
cellular
uptak
via
gymnosi
stein
et
al
avoid
liposom
technolog
associ
toxic
lipid
reagent
advanc
nucleic
acidbas
drug
treat
dyslipidemia
mipomersen
toth
obtain
fda
approv
treatment
patient
homozyg
fh
earli
press
releas
sanofi
mipomersen
apo
aso
made
sever
clinic
trial
demonstr
efficaci
mipomersen
reduc
apo
ldlc
total
cholesterol
level
well
lp
level
healthi
volunt
apo
ldlc
level
reduc
akdim
et
al
addit
mg
mipomersen
sc
weekli
heterozyg
fh
patient
treat
maxim
possibl
statin
dose
reduc
ldlc
level
treat
patient
achiev
ldlc
target
mgdl
mm
compar
group
treat
statin
efficaci
mipomersen
better
femal
men
mean
ldlc
reduct
vs
dropout
rate
mainli
caus
injectionsit
reaction
treat
patient
show
increas
liver
fat
stein
et
al
patient
homozyg
fh
treat
maxim
toler
dose
statin
mg
mipomersen
reduc
ldlc
raal
et
al
advers
side
effect
elev
transaminas
flulik
symptom
inject
site
reaction
well
sign
hepat
steatosi
frequent
found
fh
patient
genet
defici
apo
limit
maxim
toler
dose
fda
vote
approv
mipomersen
addon
therapi
patient
homozyg
fh
alreadi
treat
anoth
lipidlow
therapi
lowfat
diet
press
releas
sanofi
wherea
european
agenc
ema
approv
mipomersen
due
safeti
concern
mipomersen
new
attract
altern
ldl
apheresi
patient
apolipoprotein
sever
rnasilenc
drug
investig
clinic
trial
use
snalp
technolog
rozema
et
al
liposom
sirna
drug
press
releas
tekmira
test
dose
mgkg
proband
well
toler
without
sever
advers
side
effect
inject
site
reaction
one
proband
express
flulik
symptom
probabl
caus
innat
immun
respons
apob
snalp
drug
product
doselimit
cytokin
releas
lead
termin
develop
press
releas
develop
followup
compound
adjust
apob
sirna
tkmapob
minim
immun
stimulatori
properti
report
sever
rnabas
drug
approach
preclin
clinic
develop
alnpc
rnai
drug
deliv
stabl
nucleic
acid
lipid
particl
snalp
deliveri
technolog
rozema
et
al
aim
silenc
gene
phase
trial
perform
healthi
volunt
elev
ldlc
level
mgdl
singl
inject
dose
mgkg
week
plasma
level
ldlc
reduc
respect
effect
hdlc
level
compound
report
safe
without
sever
advers
side
effect
fitzgerald
et
al
importantli
elev
liver
enzym
observ
tempt
specul
may
better
target
antisens
approach
lower
ldl
cholesterol
level
regard
liver
toxic
compar
apolipoprotein
b
multidos
studi
dose
mgkg
circul
level
reduc
lead
decreas
ldlc
fitzgerald
et
al
new
drug
deliveri
platform
base
galnacsirna
conjug
subcutan
applic
long
durat
action
becom
possibl
nonhuman
primat
singl
dose
mgkg
alnpc
sc
knock
level
ldlc
reduct
ldlc
even
day
inject
data
support
attempt
effect
treatment
hypercholesterolemia
inject
rnai
drug
month
even
per
quarter
press
releas
alnylam
preclin
level
genesilenc
oligonucleotid
mrna
show
sc
administr
signific
specif
reduct
concentr
mrna
without
affect
express
lxr
press
releas
idera
two
antisens
drug
candid
santari
spc
phosphothio
work
via
rnase
h
mechan
investig
phase
clinic
trial
develop
termin
undisclos
reason
recent
case
acut
kidney
injuri
recoveri
report
one
patient
receiv
weekli
inject
week
multifoc
tubular
necrosi
sign
oligonucleotid
accumul
kidney
van
poelgeest
et
al
known
phosphothi
aso
bind
particularli
protein
plasma
variou
tissu
interact
polyanion
pdgf
vegf
result
high
concentr
tissu
therefor
high
efficaci
hand
result
high
concentr
liver
kidney
spleen
lead
cellular
toxic
transient
inhibit
clot
cascad
kurreck
therebi
limit
therapeut
window
phosphorothioatebas
aso
molecular
target
antisens
approach
treatment
dyslipidemia
develop
apolipoprotein
ciii
isisapociiirx
lipoprotein
lp
isisapo
rx
angiopoietinlik
iii
chylomicronemia
rare
inherit
diseas
patient
worldwid
due
increas
level
apolipoprotein
ciii
noncompetit
inhibitor
lipoprotein
lipas
tgrich
lipoprotein
catabol
lead
extrem
high
tg
plasma
level
mgdl
strongli
increas
risk
acut
pancreat
diabet
polymorph
apociii
associ
hypertriglyceridemia
apociii
lossoffunct
result
higher
tg
hydrolysi
rate
consequ
increas
tg
clearanc
lead
lower
tg
vldl
level
heterozyg
individu
apociii
lossoffunct
recent
shown
rare
lossoffunct
variant
apociii
seem
cardioprotect
tachmazid
et
al
phase
ii
clinic
program
isisapociiirx
investig
patient
extrem
high
tg
level
type
diabet
fc
famili
chylomicronemia
syndrom
receiv
mg
weekli
singl
therapi
week
plasma
level
apociii
tg
reduc
respect
wherea
hdlc
increas
addit
glucos
control
significantli
improv
reduct
placeboadjust
well
reduct
serum
fructosamin
glycat
albumin
alexand
et
al
suggest
potenti
drug
improv
peripher
insulin
sensit
patient
diabet
dyslipidemia
isisapo
rx
investig
phase
trial
healthi
volunt
lp
level
rang
mgdl
decreas
lp
level
dosedepend
reduc
oxid
proinflammatori
phospholipid
use
galnac
sirna
conjug
platform
rnai
drug
silenc
see
apociii
investig
preclin
investig
mous
model
match
human
genet
singl
scadministr
knock
apociii
level
reduc
tg
level
persist
pharmacodynam
effect
day
independ
risk
factor
cv
diseas
regul
lipid
glucos
energi
metabol
individu
increas
level
exert
hyperlipidemia
increas
risk
heart
attack
increas
arteri
wall
thick
metabol
diseas
includ
insulin
resist
inhibitor
cellular
lipas
produc
liver
genet
investig
demonstr
lossoffunct
associ
decreas
level
tg
ldlc
musunuru
et
al
sc
applic
alnang
obob
mice
result
knockdown
decreas
tg
ldlc
total
c
level
respect
addit
rnai
drug
alnang
also
antisens
drug
phase
clinic
trial
find
could
confirm
human
silencingko
could
becom
import
therapeut
option
treatment
sever
hypertriglyceridemia
mix
dyslipidemia
treatment
patient
rare
diseas
fc
famili
chylomicronemia
syndrom
hyperlipoproteinemia
type
defici
enzym
lipoprotein
lipas
essenti
breakdown
circul
chylomicron
particl
drug
adipogen
tiparvovec
glybera
approv
europ
first
gene
therapi
drug
melchiorri
et
al
restor
lpl
activ
glybera
contain
gene
human
lplvariant
tissuespecif
promot
nonrepl
vector
high
affin
muscl
tissu
gene
therapi
glybera
appli
multipl
inject
dose
gene
copieskg
bodi
weight
muscl
lower
extrem
spinal
anesthesia
strong
sedat
patient
three
day
week
glybera
inject
immunosuppress
therapi
cyclosporin
mgkg
day
mycophenolat
mofetil
gday
recommend
avoid
antibodi
format
overal
patient
receiv
gene
therapi
week
inject
patient
reduct
fast
tg
level
could
achiev
month
start
tg
level
reappear
muscl
biopsi
month
demonstr
express
lpl
gene
presenc
secret
activ
lpl
enzym
followup
observ
patient
earlier
episod
pancreat
year
indic
tendenc
less
frequent
less
sever
acut
attack
pancreat
cetp
catalyz
transfer
ce
hdl
particl
vldl
ldl
yield
cholesterolrich
apobcontain
lipoprotein
contribut
increas
deposit
cholesterol
peripher
arteri
wall
revers
transloc
tg
vldl
ldl
hdl
yield
tgrich
hdl
particl
prone
hydrolysi
lipid
hepat
lipas
mechan
hdl
particl
destabil
rapidli
clear
kidney
result
final
decreas
hdl
plasma
level
consequ
high
cetp
activ
lead
decreas
plasma
hdl
level
therefor
shift
partit
cholesterol
ldlvldl
hdl
particl
block
cetp
one
option
increas
plasma
hdl
level
find
certain
individu
lossoffunct
mutat
cetp
gene
show
elev
hdl
level
decreas
incid
chd
koizumi
et
al
inazu
et
al
trigger
search
cetp
inhibitor
find
howev
show
certain
mutat
cetp
gene
associ
increas
risk
chd
despit
high
hdlc
level
zhong
et
al
addit
anim
experi
also
show
conflict
result
regard
benefici
detriment
effect
cetp
inhibit
torcetrapib
first
cetp
inhibitor
evalu
human
clinic
trial
monotherapi
dose
mgday
abl
increas
hdl
level
respect
reduct
ldlc
mckenney
et
al
larg
clinic
trial
mgday
torcetrapib
top
mgday
atorvastatin
show
increas
hdlc
level
addit
lower
ldlc
compar
atorvastatin
alon
kastelein
et
al
studi
howev
effect
torcetrapib
progress
regress
atherosclerosi
could
demonstr
despit
increas
hdlc
level
torcetrapib
increas
systol
diastol
blood
pressur
mmhg
associ
increas
number
death
cardiovascular
noncardiovascular
caus
group
compar
atorvastatin
group
alon
mckenney
et
al
davidson
et
al
final
lead
termin
clinic
develop
anoth
cetp
inhibitor
dalcetrapib
weaker
pharmacolog
efficaci
compar
torcetrapib
show
hdlc
increas
without
effect
blood
pressur
later
could
demonstr
hypertens
activ
torcetrapib
independ
mechan
cetp
offtarget
effect
possibl
induct
elev
aldosteron
cortisol
level
forrest
et
al
dalcetrapib
investig
phase
iii
clinic
trial
patient
abil
reduc
cardiovascular
morbid
mortal
patient
recent
acut
coronari
syndrom
event
schwartz
et
al
interim
analysi
develop
drug
discontinu
advers
side
effect
due
disappoint
result
efficaci
outcom
disclos
yet
despit
failur
search
efficaci
safe
cetp
inhibitor
still
one
activ
drug
discoveri
field
novel
antiatherosclerot
drug
least
four
small
molecul
cetp
inhibitor
current
clinic
investig
anacetrapib
phase
iii
show
doubleblind
placebocontrol
trial
dose
mgday
top
statin
increas
hdlc
decreas
ldlc
without
effect
blood
pressur
serum
electrolyt
aldosteron
level
without
cardiac
advers
effect
addit
lp
level
decreas
cannon
et
al
direct
compar
trial
mgday
anacetrapib
could
increas
hdlc
compar
gday
nicotin
acid
yvancharret
et
al
potent
hdlc
increas
drug
avail
today
huge
trial
involv
patient
reveal
way
elucid
whether
anacetrapib
reduc
rate
cardiovascular
event
patient
optim
statin
therapi
evacetrapib
monotherapi
increas
hdlc
concomitantli
decreas
ldlc
dose
mgday
combin
statin
dose
mgday
evacetrapib
increas
hdlc
addit
decreas
ldlc
nichol
et
al
clinic
trial
anacetrapib
evacetrapib
demonstr
clear
benefici
chang
lipid
profil
howev
drug
also
reduc
ldlc
lp
make
difficult
differenti
elabor
contribut
benefici
effect
hdl
increas
potenti
reduct
cvd
risk
due
cetp
inhibit
mask
cetp
action
antibodi
rais
fusion
protein
certain
cetp
epitop
link
cell
epitop
tetanu
toxin
altern
approach
phase
ii
studi
treat
patient
show
year
vaccin
immun
respons
increas
hdlc
omori
longer
develop
new
cetp
vaccin
approach
use
small
peptid
fragment
cetp
protein
act
b
cell
epitop
enter
phase
trial
assess
safeti
immunogen
homepag
affiri
interest
approach
combin
cetpinhibitori
action
downregulatori
activ
one
molecul
current
phase
clinic
trial
uniqu
mode
action
suppress
transcript
part
inhibit
srebp
bind
sre
promot
suppress
srebp
express
shibata
et
al
miyosawa
et
al
summari
still
remain
demonstr
whether
pharmacolog
intervent
rais
plasma
hdl
level
inhibit
enzymat
activ
cetp
exert
robust
reduct
atherosclerosi
cardiovascular
morbid
mortal
mutant
form
milano
found
associ
low
hdlc
level
without
increas
risk
cvd
sirtori
et
al
franceschini
et
al
small
clinic
trial
iv
applic
milano
reconstitut
phospholipid
vesicl
report
induc
signific
reduct
coronari
atherosclerosi
patient
ac
week
treatment
decreas
atheroma
volum
nissen
et
al
surpris
result
trigger
research
effici
hdl
replac
therapi
milano
phospholipid
formul
investig
phase
clinic
trial
treatment
atherothrombot
diseas
ac
well
prevent
restenosi
cabg
balloon
twentyfour
healthi
individu
patient
confirm
cad
receiv
infus
dose
mgkg
follow
day
halflifetim
rang
h
group
phospholipid
prebeta
hdl
level
increas
increas
hdl
particl
size
accompani
decreas
apo
dosag
mgkg
howev
increas
tg
decreas
hdlc
observ
belliba
et
al
overal
drug
well
toler
seriou
advers
event
safeti
issu
synthet
hdl
particl
reconstitut
isol
human
plasma
soybean
phosphatidylcholin
compound
fail
phase
ii
trial
reduc
plaqu
volum
coronari
arteri
patient
suffer
recent
episod
ac
tardif
et
al
patient
ac
receiv
singl
infus
mgkg
h
signific
differ
could
detect
surrog
marker
forearm
venou
occlus
plethysmographi
despit
increas
hdlc
decreas
ldlc
chenevard
et
al
reformul
name
current
phase
ii
clinic
trial
stabl
cad
patient
gill
et
al
diditchenko
et
al
healthi
volunt
receiv
singl
dose
mgkg
increas
prebeta
stimul
macrophag
cholesterol
efflux
mediat
increas
efflux
capac
gill
et
al
mechanist
investig
suggest
infus
particl
fuse
hdl
plasma
subsequ
releas
lipidpoor
diditchenko
et
al
effect
last
least
h
indic
twice
weekli
infus
could
appropri
treatment
regimen
gill
et
al
addit
exert
antiinflammatori
effect
strong
inhibit
express
adhes
molecul
monocyt
neutrophil
decreas
proinflammatori
cytokin
chemokin
rant
diditchenko
et
al
hdlmimet
compris
recombin
apoai
complex
phospholipid
design
mimic
benefici
properti
natur
nascent
hdl
particl
healthi
volunt
increas
plasma
level
singl
infus
dosedepend
manner
similar
increas
hdlc
keyserl
et
al
rabbit
least
time
potent
mobil
cholesterol
macrophag
kastelein
placebocontrol
phase
studi
chisquar
patient
ac
given
week
weekli
infus
drug
fail
show
hdl
mimet
reduc
total
atheroma
volum
intraven
ultrasound
analysi
ivu
scan
conduct
week
last
infus
show
reduc
total
atheroma
volum
baselin
chang
significantli
differ
chang
baselin
seen
placebo
group
press
releas
cereni
tardif
et
al
clinic
trial
patient
famili
primari
hypoalphalipoproteinemia
howev
abl
reduc
carotid
arteri
mean
vessel
wall
area
measur
magnet
reson
imag
treatment
patient
dose
week
furthermor
patient
hofh
receiv
biweekli
infus
month
top
optim
ldlc
lower
therapi
includ
apheresi
carotid
arteri
mean
vessel
wall
area
well
statist
reduc
press
releas
cereni
koott
et
al
lead
orphan
drug
approv
european
medicin
agenc
ema
septemb
today
clinic
trial
hdl
replac
therapi
deliv
mix
result
efficaci
safeti
costeffect
approach
shown
futur
studi
well
invas
rout
administr
limit
widespread
use
due
reason
regard
patient
complianc
need
physician
intervent
sever
mimet
mimick
least
one
amphipath
helic
therefor
abl
associ
lipid
show
promis
result
anim
studi
oral
applic
stimul
rct
lcat
activ
offload
cholesterol
liver
via
srbi
receptor
navab
et
al
carballojan
et
al
peptid
f
contain
four
damino
acid
oral
appli
mice
abl
inhibit
lipid
peroxid
increas
activ
stimul
cholesterol
efflux
navab
et
al
xie
et
al
vakili
et
al
phase
clinic
trial
patient
cad
receiv
mg
f
oral
show
low
bioavail
bloedon
et
al
watson
et
al
efficaci
data
studi
relat
one
use
peptid
f
inconsist
regard
chang
total
cholesterol
ldlc
hdlc
tg
despit
decreas
hdl
inflammatori
index
f
bihel
peptid
deriv
apoai
five
nonpolar
amino
acid
hydrophob
side
helix
substitut
alanin
therebi
reduc
lipid
affin
second
helix
peptid
modif
found
reduc
peptid
cytotox
increas
specif
remov
cholesterol
cell
iv
applic
peptid
complex
phospholipid
apo
ko
mice
abl
rais
hdl
promot
rct
reduc
atherosclerosi
reuter
complet
new
innov
approach
increas
hdlc
pursu
resverlogix
drug
exert
activ
via
epigenet
mechan
bailey
et
al
inhibitor
bet
protein
bromodomain
extracellular
domain
includ
member
bet
protein
famili
belkina
deni
one
key
epigenet
mechan
involv
modif
chromosom
protein
acetyl
methyl
phosphoryl
catalyz
specif
enzym
modifi
amino
acid
histon
serv
bait
protein
includ
bet
protein
bind
read
epigenet
code
bet
protein
contain
two
specif
site
bromodomain
extracellular
domain
recogn
acyl
lysin
residu
histon
bound
dna
bind
bet
protein
modifi
histon
addit
cofactor
regul
gene
activ
recruit
lead
increas
gene
transcript
apolipoprotein
mimic
bind
acyl
lysin
residu
bet
therebi
trigger
cascad
increas
gene
transcript
format
phase
iib
clinic
trial
sustain
patient
establish
atherosclerosi
significantli
rais
hdlc
increas
level
larg
hdl
particl
therebi
stimul
rct
nichol
et
al
statintr
patient
chd
treat
mgday
week
show
increas
apoai
hdlc
number
larg
hdl
particl
nichol
et
al
patient
transient
signific
increas
liver
transaminas
observ
phase
placebocontrol
clinic
trial
patient
low
hdl
level
establish
chd
random
placebo
group
n
treatment
group
n
patient
receiv
either
mgday
atorvastatin
mgday
rosuvastatin
wherea
treatment
group
receiv
mg
bid
month
fail
achiev
primari
secondari
endpoint
increas
hdlc
apoai
reduc
arteri
plaqu
european
societi
cardiolog
esc
hdlc
apoai
increas
vs
placebo
group
differ
found
ldlc
vs
larg
hdl
particl
vs
hscrp
vs
wherea
liver
transaminas
increas
often
report
group
vs
primari
endpoint
medium
chang
percent
atheroma
volum
group
show
chang
vs
placebo
group
reason
failur
yet
clear
lack
efficaci
short
durat
treatment
inabl
improv
benefici
effect
statin
treatment
due
crucial
role
cell
gene
control
bet
inhibitor
may
depress
transcript
endogen
human
retrovirus
bet
proteincontain
transcript
regul
complex
also
exert
corepressor
function
belkina
deni
sinc
efficaci
data
hdlc
far
disappoint
studi
necessari
determin
valid
epigenet
approach
increas
hdl
level
overal
mysteri
regard
hdl
continu
virani
ballantyn
efficaci
hdl
increas
pharmacolog
intervent
approach
reduc
cardiovascular
morbid
mortal
still
demonstr
clinic
endpoint
trial
acyltransferas
lcat
increas
plasma
level
hdl
convert
free
cholesterol
cholesterol
ester
latter
becom
substrat
cetpcatalyz
transfer
tgrich
apobcontain
lipoprotein
exchang
tg
therebi
gener
particl
therefor
increas
lcat
activ
stimul
increas
express
exogen
deliveri
could
way
increas
function
plasma
hdl
level
stimul
rct
proof
concept
recent
demonstr
one
patient
rare
genet
diseas
famili
lcat
defici
patient
far
report
patient
lcat
defici
dramat
low
level
hdlc
pathophysiolog
phenotyp
includ
corneal
opac
fishey
diseas
anemia
splenomegali
sever
kidney
diseas
latter
major
caus
morbid
mortal
patient
baselin
hdl
level
lower
mgdl
mmoll
receiv
increas
dose
recombin
lcat
mgkg
singl
infus
week
follow
infus
mgkg
everi
week
dose
lcat
level
increas
remain
stabl
day
plasma
hdlc
level
rose
mgml
mmoll
marker
renal
function
improv
significantli
decreas
blood
urea
decreas
cystatin
c
improv
anemia
without
signific
advers
side
effect
shamburek
et
al
phase
singledos
escal
studi
volunt
stabl
atherosclerosi
receiv
singl
dose
elev
hdlc
advers
side
effect
report
day
followup
observ
busi
wire
press
find
may
stimul
search
compound
upregul
stimul
lcat
activ
novel
approach
increas
hdl
level
rct
fibroblast
growth
factor
fgf
amino
acid
protein
secret
liver
white
brown
adipos
tissu
exocrin
pancrea
regul
insulin
sensit
lipid
energi
metabol
kharitonenkov
et
al
administr
exogen
fgf
obes
diabet
rhesu
monkey
exert
profound
benefici
effect
glucos
lipid
level
well
bodi
weight
kharitonenkov
et
al
stabl
analogu
fgf
investig
placebocontrol
clinic
trial
diabet
patient
receiv
daili
sc
inject
mg
day
ldlc
level
dose
mg
reduc
total
cholesterol
respect
apolipoprotein
b
ciii
reduc
apob
apociii
furthermor
hdlc
level
increas
wherea
tg
level
strongli
decreas
addit
treatment
accompani
weight
loss
kg
strong
increas
circul
adiponectin
level
wherea
signific
effect
observ
fast
plasma
glucos
level
gaich
et
al
benefici
efficaci
multipl
metabol
paramet
deviat
metabol
disord
may
indic
fgf
analogu
could
evolv
proven
safe
novel
effect
drug
treatment
dyslipidemia
associ
metabol
disord
like
diabet
obes
metabol
syndrom
introduct
statin
clinic
practic
lovastatin
first
drug
class
henwood
heel
revolution
treatment
lipid
disord
made
reduct
ldlc
primari
goal
treatment
dyslipidemia
prevent
cvd
nation
cholesterol
educ
program
graham
et
al
tremend
clinic
efficaci
antibodi
reduc
ldlc
far
beyond
possibl
statin
mark
potenti
quantum
leap
treatment
elev
ldl
cholesterol
level
modif
pathway
despit
clinic
establish
invers
relationship
hdl
cvd
risk
enorm
effort
yet
translat
find
effect
hdlmodifi
drug
approach
unequivoc
clinic
benefit
cvd
morbid
mortal
recent
find
highlight
function
hdl
probabl
relev
factor
underli
protect
effect
hdl
help
develop
hdlmodifi
drug
benefici
clinic
efficaci
cardiovascular
endpoint
prevent
combat
atherosclerosi
clinic
consequ
major
need
clinic
develop
novel
lipidmodifi
drug
develop
new
noninvas
measur
biomark
monitor
efficaci
halt
progress
induc
regress
atherosclerosi
allow
smaller
focus
clinic
trial
stratifi
patient
popul
clinic
proofofconcept
novel
drug
approach
